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Apoptosis is a p�ysiological mode of cell deat��� w�ic� 
can be selectively triggered by cells in response to t�e 
stimuli [���]. Despite various agents can induce apoptotic 
programme in a dose-dependent manner�� searc� for new 
drugs t�at induce apoptosis is still �ig�ly desirable.
Quinazolines represent a class of drugs wit� a variety 
of biological activities�� including antimicrobial�� antiinflam-
matory�� diuretic�� anticonvulsant�� antiallergic�� anticancer�� 
and many ot�ers [4��]. It �as been s�own t�at t�ey act 
as antifolate synt�ase in�ibitors�� EGFR tyrosine kinase 
in�ibitors�� in�ibitors of di�ydrofolate reductase and tyro-
sine kinase. Some quinazolins interact wit� cytoskeleton�� 
induce apoptosis�� affect DNA topoisomerases and po-
tentiate t�e efficacy of c�emot�erapeutics [8���].
In t�e work presented�� anticancer properties of 
a newly synt�esized �-p�enoxymet�yl-�H-quinazolin-
4-one �P�Q�� were studied. P�Q was c�osen from 
series of fifteen �-substituted quinazolin-4-ones t�at 
s�own to in�ibit t�e growt� of HeLa cells [�4]. T�e 
antiproliferative�� cell cycle profile modulating and 
apoptotic properties of P�Q were studied�� comple-
mented wit� experiments elucidating t�e molecular 
mec�anism of P�Q-induced apoptosis in more detail�� 
suc� as abilities of P�Q to induce oxidative stress and 
to activate t�e caspases -��� -8 and -�.
MATERIALS AND METHODS
Drug. �-p�enoxymet�yl-�H-quinazolin-4-one 
�P�Q�� �Fig.��� was synt�esized according to Spirkova 
et al. [�4]. T�e solution of P�Q ��� m� in D�SO�� 
was stored at ��� °C�� protected from lig�t. T�e final 
concentration of D�SO in t�e medium was < �.��% 
and did not affect cell growt�.
Fig. 1. C�emical structure of �-p�enoxymet�yl-�H-quinazolin-
4-one �P�Q��
Cell line. Human promyelocytic leukemia HL-6� 
cells were maintained in RP�I-�64� medium sup-
plemented wit� ��% FCS�� ��� units/ml penicillin�� 
��� μg/ml streptomycin and � m� L-glutamine in an 
atmosp�ere of 5% CO� in �umidified air at �� °C.
Drug treatment. Exponentially growing cells were 
�arvested by centrifugation and resuspended in fres� 
medium to ac�ieve culture density of � x ��5 cells/ml. 
T�e cells were treated wit� �.���5.� μ� P�Q for �4 �. 
In experiments wit� BSO�� t�e cells were exposed to 
�.5 m� BSO �4 � prior to P�Q treatment. Cell number 
and viability were determined by trypan blue staining.
Cell cycle measurement. Untreated and drug-
treated cells ��.5 x ��6�� were �arvested�� was�ed twice in 
p�osp�ate-buffered saline �PBS�� and exposed to �.�5% 
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Triton X-��� in PBS supplemented wit� RNase A �5� μg/
ml�� for �5 min at �� °C. Afterwards�� DNA was stained by PI 
�5� μg/ml�� for �5 min at 4 °C. Samples were analyzed by a 
Coulter Epics Altra flow cytometer wit� t�e use of software 
provided by t�e manufacturer. A minimum of ������� cells 
per sample was analyzed at a flow rate of ��� cells/s.
Electrophoretic analysis of apoptotic DNA frag-
mentation. Untreated and drug-treated cells �� x ��6�� 
were �arvested�� was�ed in PBS and lysed wit� ��� µl of 
solution ��� m� Tris�� �� m� EDTA�� �.5% Triton X-����� 
supplemented wit� proteinase K �� mg/ml��. Samples 
were t�en incubated at �� °C for � � and �eated at �� °C 
for �� min. Following lysis�� RNase A ���� μg/ml�� was 
added and repeated incubation at �� °C for � � followed. 
T�e samples were subjected to electrop�oresis at 4� V 
for � � in �.5% �w/v�� agarose gel complemented wit� 
EtBr �� μg/ml��. Separated DNA fragments were visuali-
zed using UV transilluminator ��54 nm��.
Caspase-3 activity assay. Cells were treated   
wit� ve�icle �D�SO�� or 5.� and ��.� μ� P�Q for �4 �. 
Cell lysates were prepared and caspase-� activity was 
measured according to t�e manufacturer’s protocol 
 �CaspACET� Assay System�� Promega Corporation�� USA��. 
Briefly�� an equal amount of cell lysate proteins �adjusted 
to �� μl wit� lysate buffer�� was added to t�e reaction mix-
tures containing colorimetric substrate peptide specific 
for caspase-� �Ac-DEVD-pNA��. T�e plate was incubated 
in t�e dark for 4 � at �� °C. Absorbance was determined 
after 8 � using a spectrop�otometric microplate reader        
�Humareader�� U.K.�� 4�5 nm��. Protein concentrations 
were determined by Bradford met�od.
Caspase-8 and caspase-9 activities assays. Cells 
were treated wit� ve�icle �D�SO�� or ��.� μ� P�Q for 
�4 �. Caspase-8 and caspase-� activities were measu-
red according to t�e manufacturer’s protocol �CaspGloT� 
Assay�� Promega Corporation�� USA��. Briefly�� ��� μl of 
Caspase-GloT� 8 Reagent �containing Z-LETD-aminoluci-
ferin�� and ��� μl of Caspase-GloT� � Reagent �containing 
Z-LEHD-aminoluciferin���� respectively�� were added to t�e 
test tube wit� ��� μl of cell suspension containing 5������ 
cells and mixed. T�e luminescence signal was measured 
after��minusingaGlomax     TX ��/�� Luminometer w/Dual 
Auto-Injector �Turner BioSystems�� USA��.   
Glutathione assay. To determine total glutat�ione 
�GSHt���� �� μl of cell lysate was incubated at �� °C wit� 
8� μl of �.� m� NADPH�� ��5 m� sodium p�osp�ate 
buffer wit� 6.� m� EDTA�� pH �.5�� and �� μl of 6 m� 
DTNB. After addition of �� μl of �5 U/ml GSH reductase 
t�e c�ange in absorbance at 4�� nm was measured using 
Spekol ���. To measure oxidized glutat�ione �GSSG���� 
reduced glutat�ione �GSH�� in samples was derivatized 
by adding �.� μl of �� m� 4-vinylpyridine per ��.5 μl 
solution and mixed vigorously for � min. GSSG was mea-
sured in t�e same manner as GSHt. T�e concentration 
of GSH was calculated as t�e difference between GSHt 
and GSSG. In parallel experiments�� t�e number of cells 
was determined in order to express t�e results as t�e 
amount of GSHt �nanomoles�� per ��6 cells.
Statistical analysis. Data are presented as t�e 
means ± S.D. of t�ree independent experiments. T�e 
median and t�e standard deviation were calculated 
using Excel ��icrosoft Office�� Version �8��. T�e statis-
tical significance of t�e results obtained was evaluated 
by t�e Student’s t-test�� wit� probability values of �.�5 
being considered as significant.
RESULTS
PMQ inhibits growth and induces apoptosis in 
HL-60 cells. Growt� of HL-6� leukemia cells exposed 
to �.���5.� μ� of �-p�enoxymet�yl-�H-quinazolin-
4-one �P�Q�� was monitored wit�in �4 �. As s�own in 
Fig. �a�� P�Q induced concentration-dependent in�i-
bition of cell proliferation wit� IC5� of ��.8 ± �.� μ�. As-
sessment of cytoplasmic membrane integrity revealed 
t�at P�Q at tested concentrations did not affect t�e 
membrane integrity of treated cells significantly. T�e 
growt� in�ibition induced by P�Q was accompanied 
by apoptotic cell deat� and cell cycle profile c�anges. 
As presented in Fig. �b�� 5.� μ� P�Q induced sig-
nificant apoptotic DNA fragmentation. Induction of 
apoptosis was confirmed by an appearance of sub-G� 
cell population. Cell cycle analysis revealed t�at P�Q 
induced concentration-dependent G�/� cell cycle ar-
rest �5�.� ± �.�% for cells treated wit� �5.� μ� P�Q 
compare to ��.6 ± �.8% for untreated cells�� wit� a 
marked loss of cells in G�/G� and S p�ases �Table ���.
Fig. 2. Effect of �-p�enoxymet�yl-�H-quinazolin-4-one �P�Q�� 
on proliferation of HL-6� leukemia cells. Data represent mean 
values ± S.D. of t�ree independent experiments �a��. Apoptotic 
DNA fragmentation induced by P�Q in HL-6� leukemia cells. T�e 
figure is representative of t�ree independent experiments �b��
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Table 1. Effect of 2-phenoxymethyl-3H-quinazolin-4-one (PMQ) on cell cycle 
profile of HL-60 leukemia cells after 24 h treatment
PMQ sub-G0 G0/G1 S G2/M
— 1.5 ± 0.9 39.2 ± 1.9 49.2 ± 4.2 11.6 ± 2.8
5.0 μM 4.7 ± 1.3 40.9 ± 2.5 37.6 ± 3.1 21.5 ± 3.9
10.0 μM 12.6 ± 2.8 29.7 ± 3.6 30.4 ± 2.9 39.9 ± 2.6
15.0 μM 24.5 ± 2.9 21.1 ± 2.9 25.7 ± 4.4 53.2 ± 3.2
Note: Data represent mean values ± S.D. of three independent experiments.
PMQ activates caspases and induces oxidative 
stress response in HL-60 cells. To address w�ic� 
caspases are activated by P�Q treatment�� HL-6� 
cells were treated wit� 5.� μ� and ��.� μ� P�Q for 
�4 �. As s�own in Fig. �a�� activity of caspase-� in cells 
treated wit� 5.� μ� P�Q was detected to be �.8 times 
�ig�er �P < �.������ and cells treated wit� ��.� μ� P�Q 
�ad above 5.� times �ig�er activity �P < �.���� of t�e 
caspase-� compare to untreated cells. Activity of cas-
pase-� in cells treated wit� ��.� μ� P�Q was increased 
about �.� times compare to untreated cells �P < �.����. 
Caspase-8 was not activated significantly �Fig. �b��.
Fig. 3. Activation of caspase-� �a�� and caspase-8 and -� �b�� 
by �-p�enoxymet�yl-�H-quinazolin-4-one �P�Q�� in HL-6� 
leukemia cells. Data represent mean values ± S.D. of t�ree 
independent experiments
Note: cis-Pt = cisplatin; i = caspase-� in�ibitor; *P < �.�5; 
**P < �.��.
Reactive oxygen species �ROS�� play an important 
role in signalling leading to apoptosis. �any c�emicals 
elevate t�e level of ROS�� but only a few are able to c�ange 
t�e redox state of cell significantly�� wit� no damage to t�e 
cytoplasmic membrane. To examine if P�Q �as a poten-
tial to c�ange t�e redox state of cells�� levels of reduced 
glutat�ione �GSH�� and oxidized glutat�ione �GSSG�� were 
measured. As presented in Table ��� t�e cells treated wit� 
�.5���.� μ� P�Q elevated t�e level of total GSH �GSH + 
GSSG = GSHt��. W�ile t�e level of GSH in cells treated 
wit� ��.� μ� P�Q increased above � times �from 5.8� ± 
�.5� to ��.�� ± �.56 nmol/��6 cells���� t�e content of GSSG 
increased nearly � times �from �.�4 ± �.�6 to �.68 ± �.�� 
nmol/��6 cells��. GSSG/GSH ratio c�anged from �.�4� to 
�.�6��� s�owing t�at P�Q induced significant c�anges in 
redox state of HL-6� cells �P < �.����.
Table 2. Effect of 2-phenoxymethyl-3H-quinazolin-4-one (PMQ) on 
GSSG/GSH ratio in HL-60 leukemia cells after 24 h treatment
PMQ GSH GSSG GSSG/GSH
– 5.82 ± 0.53 0.24 ± 0.06 0.041
2.5 μM 8.57 ± 0.26 0.39 ± 0.08 0.046*
5.0 μM 10.00 ± 0.33 0.52 ± 0.11 0.052**
10.0 μM 10.97 ± 0.56 0.68 ± 0.09 0.062**
Note: Cellular levels of GSH and GSSG are in nmol per 106 cells. Data represent 
mean values ± S.D. of three independent experiments. *P < 0.05; **P < 0.01.
Pretreatment of HL-6� cells wit� but�ionine sulfoxi-
mine �BSO���� a specific in�ibitor of γ-glutamyl-cysteine 
synt�etase�� was applied to evaluate t�e involvement 
of ROS in P�Q-induced apoptosis. Incubation of cells 
wit� �.5 m� BSO for �4 � decreased GSHt content 
from 6.�6 ± �.6� nmol/��6 cells to �.55 ± �.�� nmol/��6 
cells �Fig. 4a��. T�e P�Q did not increase t�e level of 
GSHt in cells pretreated wit� BSO. BSO-pretreated 
cells were more prone to die by apoptosis w�en treated 
wit� �.5 μ� P�Q�� confirming t�e important role of ROS 
in apoptotic signalling induced by P�Q �Fig. 4b��.
Fig. 4. Effect of �-p�enoxymet�yl-�H-quinazolin-4-one �P�Q�� and 
but�ionine sulfoximine �BSO�� on total glutat�ione �GSHt�� level in 
HL-6� leukemia cells. Data represent mean values ± S.D. of t�ree 
independent experiments. GSHt level for untreated cells was 6.5 ± 
�.� nmol GSH/��6 cells �a��. Effect of BSO treatment on apoptotic 
DNA fragmentation induced by P�Q in HL-6� leukemia cells. T�e 
figure is representative of t�ree independent experiments �b��
*P < �.�5; **P < �.��.
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DISCUSSION
�any quinazolines ex�ibit antiproliferative activity 
against various tumor cell lines. However�� mec�anism 
responsible for t�eir antiproliferative activity varies 
considerably. It includes induction of cell cycle arrest�� 
direct cytotoxicity t�roug� t�e initiation of apoptosis�� 
effect on membrane integrity�� in�ibition of antifolate 
synt�ase�� EGFR tyrosine kinase�� di�ydrofolate reduc-
tase or tyrosine kinase�� or effect on activity of DNA 
topoisomerases [4���].
In t�is study�� anticancer properties of a newly 
synt�esized �-p�enoxymet�yl-�H-quinazolin-4-one 
�P�Q�� were studied. P�Q was c�osen as t�e best 
candidate from series of fifteen newly synt�esized 
�-substituted quinazolin-4-ones. T�ese quinazolines 
�ave been s�own to in�ibit growt� of HeLa cells [�4]. 
T�e antiproliferative�� cell cycle profile modulating 
and apoptotic properties of P�Q are presented�� 
complemented wit� experiments s�owing t�at P�Q 
induced apoptosis t�roug� mitoc�ondrial/caspase-� 
dependent pat�way�� and experiments confirming t�e 
importance of ROS in signalling leading to P�Q-in-
duced apoptosis.
Antiproliferative activity of P�Q occured at con-
centrations as low as �.� μ� and 5.� μ� of P�Q was 
required to induce features typically associated wit� 
apoptosis. Analysis of HL-6� cells treated wit� 5.� μ� 
of P�Q provided clear evidence t�at P�Q-treated 
cells were dying by apoptosis as sub-G� cell fraction 
�Table ����� apoptotic DNA fragmentation �Fig. ��� b�� 
and active forms of caspase-� and caspase-� �Fig. ��� 
were detected. No significant cytoplasmic membrane 
damage was observed in conjunction wit� observed 
apoptotic features. T�ese c�anges closely resemble 
t�ose induced by cisplatin�� t�e clinically used antican-
cer drug�� t�at was used in our experiments as positive 
control. Additionally to apoptosis�� block of cells in G�/� 
p�ase and decrease in percentage of cells in G�/G� 
and S p�ases were observed �Table ���. Experiments 
leading to elucidation of t�e molecular mec�anism 
by w�ic� P�Q induces cell cycle profile c�anges 
are in progress. It is possible t�at P�Q in�ibits some 
cyclin-dependent kinases or some ot�er regulatory 
proteins t�at are directly involved in regulation of cell 
cycle progression. It �as been s�own previously t�at 
some quinazoline derivatives are potent in�ibitors of 
cyclin-dependent kinases [�5���].
Cell proliferation and survival are influenced by 
reactive oxygen species. Previous reports s�owed t�at 
some drugs can induce elevation of ROS levels during 
induction of apoptosis [�8����]. Here�� we s�owed t�at 
in P�Q-induced apoptosis ROS play an important role 
in signalling leading to apoptotic cell deat�. Increased 
levels of GSHt and GSSG indicated t�e presence of 
significant oxidative stress in cells treated wit� P�Q 
for �4 �. Additionally�� pretreatment of cells wit� BSO�� 
t�e in�ibitor of glutat�ione synt�esis�� sensitized t�e 
cells to P�Q-induced apoptosis. It �as been s�own pre-
viously t�at depletion of GSH sensitized cancer cells to 
t�erapeutic efficacy of some drugs�� w�ic� anticancer 
potential depends on ROS production [���� ��].
T�ere is always a temptation to extrapolate t�e sig-
nificance of in vitro concentration based cell responses 
to in vivo response. In vivo experiments using L����-
bearing mice s�owed t�at P�Q prolonged t�e survival 
rate of leukemia bearing mice significantly�� confirming 
t�e anticancer activity of P�Q �P < �.������. T�erapeu-
tic index of P�Q was comparable to t�erapeutic index 
of cisplatin �our unpublis�ed results��.
In summary�� results of t�is study clearly demon-
strate t�at P�Q is a promising anticancer drug s�ow-
ing cytostatic and apoptotic effects mainly t�roug� 
mitoc�ondrial/caspase-� dependent pat�way.
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ИНГИБИРОВАНИЕ РОСТА И АПОПТОЗ, ИНДУЦИРОВАННЫЕ 
2‑ФЕНОКСИМЕТИЛ‑3Н‑ХИНАЗОЛИН‑4‑ОНОМ, В ЛЕйКОЗНЫХ 
КЛЕТКАХ ЛИНИИ HL‑60
Цель: изучить антипролиферативную активность нового синтезированного 2-феноксиметил-3Н-хиназолин-4-она (PMQ). 
Материалы и методы: антипролиферативную активность PMQ определяли по отношению к клеткам лейкоза линии HL-60 
в тесте с трипановым синим при стандартном подсчете клеток. Апоптоз и клеточный цикл оценивали с помощью проточной 
цитометрии и анализа фрагментации внутриядерной ДНК. Активацию каспаз и изменения уровня глутатиона определяли 
колориметрическими или люминисцентными методами. Результаты: PMQ индуцирует дозозависимую цитотоксичность 
в клетках линии HL-60 (IC50 при 10,8 ± 0,9 μM). При проведении анализа ДНК с применением проточной цитометрии 
и определением формирования апоптической лестницы было показано, что PMQ активно индуцирует апоптоз и блокаду 
клеточного цикла в G2/M фазе митоза и выраженной потерей клеток в G0/G1 и S фазах. Кроме того, была достоверно повышена 
активность каспазы-3 и -9 и выраженно увеличен уровень окисленного глутатиона. Применение бутионин сульфоксимина 
привело к угнетению синтеза глутатиона и повышению чувствительности клеток HL-60 к PMQ, что подтверждает факт 
участия РФК в PMQ-индуцированном апоптозе. Выводы: PMQ проявил себя как потенциальное противоопухолевое средство 
против клеток лейкоза человека HL-60 с выраженным цитостатическим и проапоптическим действием. 
Ключевые слова: хиназолин, лейкоз, апоптоз, блокада клеточного цикла.
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